Yazarlar : Pandya C, Hashmi S, Gertz M et al

Yayın : Clin Transplant

Yayın Yılı : 2014

Pubmed Linki : http://www.docguide.com/cost-effectiveness-analysis-early-versus-late-autologous-stem-cell-transplantation-asct-multiple-mye?tsid=5

Konu : Kemik İliği Nakli

Literatür İçeriği :  BACKGROUND Autologous stem cell transplant (ASCT) is the current standard of care for most Multiple Myeloma (MM) patients who are transplant eligible, yet the timing of ASCT is disputed due a similar overall (OS) and progression free survival with an early (eASCT) or a delayed (dASCT) approach.

OBJECTIVE We developed a decision analytic model to perform cost-effectiveness analysis of the two commonly used treatment strategies for MM.

METHODS Data on disease progression and treatment effectiveness came from 2001-2008 cohort treated at the Mayo Clinic and from published studies. Cost analysis was performed from a third party payer perspective.

RESULTS The Consumer Price Index adjusted 2012 costs of eASCT and dASCT were $249236 and $262610 respectively. eASCT cohort had a benefit of 2.06 quality adjusted life years (QALY), 0.18 QALY more than dASCT implying that eASCT is preferred (dominant) over dASCT. The most critical variables in one-way sensitivity analysis were Treatment Related Mortality and OS associated witheASCT strategy.

CONCLUSIONS We conclude that eASCT, could potentially be a relatively cost-effective treatmentoption for appropriate MM patients, and these results would help patients, providers and payers in decision making for timing of ASCT. This article is protected by copyright. All rights reserved.

Literatür Arşivi